Introduction
============

Fibrosis or excessive extracellular matrix (ECM) accumulation results in the distortion of tissue architecture and organ dysfunction. Fibrotic diseases are the major cause of increasing morbidity and mortality, contributing to 45% of deaths worldwide.^[@bib1]^ Myofibroblasts are the major ECM-producing cells in many pathological conditions, including organ fibrosis and cancer.^[@bib2],\ [@bib3],\ [@bib4],\ [@bib5]^ Myofibroblasts, depending on the etiology and organ,^[@bib1],\ [@bib6]^ are derived from various cell types, including resident fibroblasts, stellate cells, bone marrow-derived mesenchymal stem cells, epithelial cells via the epithelial--mesenchymal transition^[@bib7],\ [@bib8],\ [@bib9]^ and endothelial cells via the endothelial--mesenchymal transition^[@bib10]^ processes. In addition to ECM production and remodeling, myofibroblasts provide tissue stiffness due to their contractile nature and elicit pro-angiogenic and pro-inflammatory signals in the form of cytokines and growth factors.^[@bib1],\ [@bib3],\ [@bib6],\ [@bib11],\ [@bib12]^ Myofibroblasts are therefore an attractive and promising cellular target for the diagnosis of fibrotic diseases and potential antifibrotic therapies.^[@bib13],\ [@bib14],\ [@bib15]^

Interactions between cells and their extracellular microenvironment are primarily mediated by a family of cell surface receptors known as integrins, which are recognized as key molecules involved in myofibroblast differentiation.^[@bib16],\ [@bib17]^ Integrins are heterodimeric transmembrane receptors composed of α and β subunits that can combine to form 24 different integrin heterodimers.^[@bib18]^ Integrins regulate cytoskeletal dynamics, thereby influencing a number of crucial cellular processes, for example, cell adhesion, migration and differentiation.^[@bib19]^ Integrins also have a key role in the activation of growth factors such as transforming growth factor beta (TGFβ); for instance, RGD-binding αv integrins have been shown to be master regulators of TGFβ activation in different fibrotic models.^[@bib17],\ [@bib20],\ [@bib21]^ Because integrins have profound effects on fibrosis in multiple organs, it might be, therefore, of utmost importance to understand/elucidate the regulatory roles of integrins and to define the strategies of modulating integrins for the development of effective antifibrotic approaches.

Accumulation of collagens (predominantly collagen I) in liver fibrosis and other fibrotic tissues is a common characteristic in fibrotic diseases. Among four collagen receptors, α1β1, α2β1, α10β1 and α11β1,^[@bib22]^ integrin α11β1 preferentially binds to type I collagen^[@bib23]^ and has been shown to be expressed on cultured embryonic fibroblasts^[@bib24]^ and cardiac fibroblasts.^[@bib25]^ α11β1 has been shown to be upregulated by TGFβ^[@bib26],\ [@bib27]^ and regulates embryonic mesenchymal cell differentiation on the collagen matrix.^[@bib25],\ [@bib27],\ [@bib28]^ More recently, the role of integrin α11β1 was implicated in inducing tumor growth and the metastatic potential of small-cell lung carcinoma cells.^[@bib29]^ However, the functional significance of integrin alpha 11 (ITGA11), its cellular distribution and contribution to fibrotic diseases remains largely undefined.

In this study, we examined the expression and localization of ITGA11 in human organ fibrosis, including liver cirrhosis, renal fibrosis and lung fibrosis, and have assessed the significance of ITGA11 during TGFβ-induced trans-differentiation of hepatic stellate cells to myofibroblasts. Furthermore, we investigated the signaling pathway that regulates ITGA11 expression and liver fibrogenesis.

Materials and methods
=====================

Human tissues
-------------

Human liver specimens were obtained from the autopsy of patients with liver cirrhosis (*n*=5) anonymously provided by the Laboratory Pathology Netherlands (LabPON) and Mount Sinai Hospital, New York, USA. Normal liver tissue (*n*=4) was collected from patients receiving hepatic resections for non-tumoral diseases, including hepatic adenoma and focal nodular hyperplasia. Nephrectomy specimens (*n*=4) used in this study were obtained from renal transplant recipients with chronic transplant dysfunction and were anonymously provided by the Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, Groningen, The Netherlands. Fibrotic (*n*=5) and non-fibrotic (*n*=5) lung tissues were collected at Mount Sinai Hospital from the patients with lung disease, including pneumothorax and lung cancer. Upon Institutional Review Board approval and after written informed consent from patients, the tissue specimens were collected. The use of human tissues was approved by the respective Local Medical Ethics Committee, and the experimental protocols were performed in accordance with institutional guidelines and regulations.

Cell lines
----------

Primary Human hepatic stellate cells (HSCs) were purchased from Zen-Bio (Durham, NC, USA) and were grown in stellate cell growth medium SteCM (ScienCell, Carlsbad, CA, USA) according to the manufacturer's instructions. HepG2 and THP1 cells were purchased from ATCC (Manassas, VA, USA) and ECACC (Sigma, St Louis, MO, USA), respectively, and were cultured in Dulbecco's modified Eagle's medium and RPMI-1640 medium (Lonza, Verviers, Belgium), supplemented with 2 m[M]{.smallcaps} L-glutamine, 10% fetal bovine serum (FBS, Lonza) and antibiotics (50 U ml^−1^ Penicillin and 50 μg ml^−1^ streptomycin, Sigma) respectively. No cell line used in this paper is listed in the database of commonly misidentified cell lines that is maintained by the International Cell Line Authentication Committee (<http://iclac.org/databases/cross-contaminations/>). All cell lines were tested negative for mycoplasma contamination.

Stable ITGA11 knockdown in HSCs
-------------------------------

To generate stable ITGA11 knockdown (ITGA11-KD) cells, primary HSCs were transfected with lentiviral shRNA ITGA11 plasmids (Santa Cruz Biotechnology, Dallas, TX, USA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) as per the manufacturer's instructions. Control cells were transfected with control/scrambled shRNA plasmid. After 24 h of transfection, stably transfected cells were selected by 2 μg ml^−1^ puromycin (Invitrogen) for 6--8 weeks. ITGA11-KD and control cells were evaluated for the effects on contractility, migration/wound healing and several fibrotic parameters using staining and quantitative PCR (qPCR).

3D collagen-I gel contraction assay
-----------------------------------

A collagen suspension (5 ml) containing 3.0 ml of collagen G1 (5 mg ml^−1^, Matrix Biosciences, Morlenbach, Germany), 0.5 ml of 10 × M199 medium (Sigma), 85 μl of 1 [N]{.smallcaps} NaOH (Sigma) and sterile water was mixed with 1.0 ml (2 × 10^6^) of cells. The collagen gel and cell suspension (0.6 ml per well) was plated in a 24‐well culture plate and was allowed to polymerize for 1 h at 37 °C. For the effect studies, polymerized gel was incubated with 1 ml of 0.5% FBS-containing medium with or without human recombinant TGFβ (5 ng ml^−1^) (Peprotech, Rocky Hill, NJ, USA) together with 10 μM LDE225 (Erismodegib, Selleckchem, Boston, NY, USA) followed by detachment of the gels from the culture wells. For other experiments, medium with or without TGFβ was added before gel detachment. Photographs were made with a digital camera at different time points (0, 24, 48 and 72 h). The size of the gels was digitally measured and normalized with their respective well size in each image. Gel contraction experiments were performed in duplicate in three independent experiments.

Wound-healing assay
-------------------

Cells were plated in 12-well culture plates (1 × 10^5^ cells per well) for 24 h and were starved overnight in 0.5% FBS-containing medium. A standardized scratch was made using a 200-μl pipette tip fixed in a holder. Cells were then washed twice and were incubated with and without 5 ng ml^−1^ TGFβ. To measure the migratory response of the cells into the scrape wounds, microscopic photographs were taken at 0 and 24 h. Images were analyzed using NIH ImageJ software (NIH, Bethesda, MD, USA) to calculate the area of the scratch wound and were represented as the percentage of wound healed relative to the control wells. Wound-healing experiments were performed in duplicate in three independent experiments.

Alamar blue assay
-----------------

To assess the effects on proliferation, cells (control HSCs and ITGA11-KD HSCs) plated in 96-well plates were serum starved for 24 h and were then incubated with fresh medium with or without TGFβ (5 ng ml^−1^) for 24 and 48 h. At the indicated time points, cells were incubated with Alamar Blue reagent (Invitrogen) for 4 h. The results are represented as the percentage of cell viability. All measurements were performed in duplicate in four independent experiments.

Hedgehog parameters and the effect of hedgehog ligand on human control HSCs and ITGA11-KD HSCs
----------------------------------------------------------------------------------------------

Cells were seeded in 12-well plates (8 × 10^4^ cells per well) and were cultured overnight. Cells were serum-starved for 24 h and then were incubated with 5 μg ml^−1^ of Shh ligand (Peprotech) for 24 h. Cells were lysed with RNA lysis buffer to perform quantitative real-time PCR analysis for hedgehog signaling pathway parameters and ITGA11 expression. qPCR analysis was performed in at least three independent experiments.

*In vitro* effects of Hedgehog inhibitor in human HSCs
------------------------------------------------------

Cells were seeded in 24-well plates (3 × 10^4^ cells per well for staining) and 12-well plates (8 × 10^4^ cells per well for qPCR analysis) and were cultured overnight. To assess the effects on fibrotic parameters, cells were serum-starved for 24 h and then were incubated with starvation medium alone, 10 μ[M]{.smallcaps} LDE225 (Erismodegib) and 5 ng ml^−1^ TGFβ1 for 24 h. Cells (24-well plates) were then fixed with chilled acetone:methanol (1:1) for 20 min, dried and stained for collagen-I, alpha smooth muscle actin (α-SMA) and vimentin (refer to [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). In addition, cells (12-well plates) were lysed with RNA lysis buffer to perform quantitative real-time PCR analyses. Staining and qPCR analysis was performed in at least three independent experiments.

Atomic force microscopy (AFM)
-----------------------------

All AFM measurements were carried out using a Bioscope Catalyst AFM with a Nanoscope V controller (Bruker, Santa Barbara, CA, USA) mounted on an inverted microscope (Axiovert 200, Carl Zeiss, Heidelberg, Germany). The AFM instrument was equipped with a 150 × 150 μm^2^ scanner with a vertical range of 25 μm. The optical microscope was used to select the desired cell and to position the AFM tip. A rectangular silicon nitride cantilever (NSC36, type C, MikroMasch, Wetzlar, Germany) with a force constant of ∼0.6 N m^−1^ was used. Fixed cells (fixed using 4% paraformaldehyde) were imaged with 512 × 512 pixels^[@bib2]^ in the contact mode in air at a scan rate of 1 Hz. Multiple scans were acquired to image the whole cell. At least 4--5 cells per condition were imaged to obtain representative images. All the AFM images were processed by the Nanoscope Analysis software (Bruker).

*Ex vivo* organotypic culture of clinical liver tissue
------------------------------------------------------

De-identified liver tissues were obtained from liver surgeries performed at Mount Sinai Medical Center, and anonymous use was approved by the institutional review board. Fresh liver tissues were sliced into 300-μm-thick tissue sections using the Krumdieck Tissue Slicer MD6000 (Alabama Research and Development, Munford, AL, USA) and were cultured with Williams' medium E supplemented with 10% FBS, 100 U ml^−1^ penicillin, 100 μg ml^−1^ streptomycin and 2.5 μg ml^−1^ amphotericin B on a heated shaker (37 °C) with medium alone, 10 μ[M]{.smallcaps} or 15 μ[M]{.smallcaps} LDE225 for 48 h as described earlier.^[@bib30]^ Harvested tissues were snap-frozen for RNA extraction.^[@bib31]^ These experiments were performed in three patients (*n*=3) with three liver slices per patient individually treated and combined for further analysis.

Animal experiments
------------------

All the animal experiments in this study were performed in strict accordance with the guidelines and ethical regulations for the Care and Use of Laboratory Animals, Utrecht University, The Netherlands. The protocols were approved by the Institutional Animal Ethics Committee of the University of Twente, The Netherlands.

CCl~4~-induced liver fibrosis mouse model
-----------------------------------------

Male C57BL/6 mice (8--10-week old; *n*=5 per group) were treated with intraperitoneal injections with olive oil or carbon tetrachloride (CCl~4~, 1 ml kg^−1^ prepared in olive oil) twice weekly for 8 weeks and killed, and then the livers and other organs were collected for subsequent analysis.

CCl~4~-induced acute liver injury mouse model
---------------------------------------------

Male C57BL/6 mice were treated with a single intraperitoneal injection of olive oil or CCl~4~ (1 ml kg^−1^ in olive oil) at day 1. At days 2 and 3, CCl~4~-treated mice received subcutaneous administration of 10 mg kg^−1^ Hedgehog inhibitor LDE225 prepared in 1% dimethyl sulfoxide and 5% β-hydroxycyclodextrin or vehicle treatment (1% dimethyl sulfoxide/5% β-hydroxycyclodextrin/phosphate-buffered saline) (*n*=5 per group). At day 4, all mice were killed, and the livers were harvested.

UUO kidney fibrosis mouse model
-------------------------------

Male C57Bl/6 mice (8--10 weeks old, *n*=5 per group) were subjected to unilateral ureteral obstruction (UUO) by double ligation of the left ureter proximal to the kidney. Right kidneys were used as contralateral controls. Kidneys were harvested 3 and 7 days after surgery.

Immunohistochemistry and immunofluorescence
-------------------------------------------

Liver tissues were harvested and transferred to Tissue-Tek OCT embedding medium (Sakura Finetek, Torrance, CA, USA) and snap-frozen in 2-methyl butane chilled in dry ice. Cryosections (4 μm) were cut using a Leica CM 3050 cryostat (Leica Microsystems, Nussloch, Germany). The sections were air-dried and fixed with acetone for 10 min. Cells or tissue sections were rehydrated with phosphate-buffered saline and were incubated with the primary antibody (refer to [Supplementary Table 1](#sup1){ref-type="supplementary-material"}) for 1 h at room temperature. Cells or sections were then incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. Next, the samples were incubated with horseradish peroxidase-conjugated tertiary antibody or donkey anti-goat Alexa 594-labeled tertiary antibody (Life Technologies, Gaithersburg, MD, USA) for 1 h, followed by washing three times with 1 × phosphate-buffered saline. Thereafter, peroxidase activity was developed using the AEC (3-amino-9-ethyl carbazole) Substrate Kit (Life Technologies) for 20 min, and nuclei were counterstained with hematoxylin (Fluka Chemie, Buchs, Switzerland). For tissue sections, endogenous peroxidase activity was blocked by 3% H~2~O~2~ prepared in methanol. Cells or sections were mounted with Aquatex mounting medium (Merck, Darmstadt, Germany). The staining was visualized, and the images were captured using light microscopy (Nikon eclipse E600 microscope, Nikon, Tokyo, Japan). For immunofluorescence, sections were mounted with DAPI (4,6-diamidino-2-phenylindole)-containing mounting medium (Sigma) and were examined using the Hamamatsu NanoZoomer Digital slide scanner 2.0HT (Hamamatsu Photonics, Bridgewater, NJ, USA). Cells were also stained with Phalloidin (Life Technologies; 1:200 dilution) for 1 h to visualize F-Actin filaments.

Western blotting analysis
-------------------------

Cells were lysed in RIPA buffer (Pierce Thermoscientific, Rockford, IL, USA) containing protease inhibitor cocktail and phosphatase inhibitors (Roche Diagnostics, Mannheim, Germany). The samples were boiled in standard protein sample buffer and were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis with 4--20% Tris-glycine gels (Life Technologies) followed by protein transfer onto a polyvinylidene difluoride membrane. The membranes were developed according to the standard protocols using primary and secondary antibodies (refer to [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). The bands were visualized using ECL detection reagent (Perkin Elmer Inc., Waltham, MA, USA) and were photographed using the FluorChem M Imaging System (ProteinSimple, Alpha Innotech, San Leandro, CA, USA).

Quantitative real-time PCR and RT^2^ profiler PCR array
-------------------------------------------------------

Total RNA from cells and liver tissues was isolated using the GenElute Total RNA Miniprep Kit (Sigma) and SV total RNA isolation system (Promega Corporation, Madison, WI, USA), respectively, according to the manufacturers' instructions. The RNA concentration was quantitated using a UV spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Total RNA (1 μg) was reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). All primers were purchased from Sigma-Genosys (Haverhill, UK). Real-time PCR was performed using the 2 × SensiMix SYBR and Fluorescein Kit (Bioline GmbH, QT615-05, Luckenwalde, Germany), 20 ng of cDNA and pretested gene-specific primer sets (listed in [Supplementary Tables 2 and 3](#sup1){ref-type="supplementary-material"}). The cycling conditions for the Bio-Rad CFX384 Real-Time PCR detection system were 95 °C for 10 min, 40 cycles of 95 °C/15 s, 58 °C/15 s and 72 °C/15 s. Finally, cycle threshold (Ct) values were normalized to the reference gene GAPDH (glyceraldehyde 3-phosphate dehydrogenase), and fold changes in expression were calculated using the 2^−ΔΔCt^ method. For the RT^2^ profiler array, RNA (500 ng) from ITGA11-KD cells and control cells was reverse transcribed using the RT^2^ First Strand Kit (SABiosciences, Frederick, MD, USA), and qPCR was performed using the human fibrosis PCR array (RT^2^ Profiler PCR Array PAHS-120Z, SABiosciences) as per the manufacturer's instructions. Six house-keeping genes (ACTB, B2M, GAPDH, HPRT1, RPLP0 and HGDC), RT controls and PCR controls were included in each run. PCR array data were analyzed using the web-based software 'RT^2^ Profiler PCR Array Data Analysis v. 3.5', available at the manufacturer's website.

ITGA11 mRNA expression in the human cohort from the public database
-------------------------------------------------------------------

ITGA11 mRNA expression was assessed in the publicly available transcriptome data sets of liver tissue from patients with non-alcoholic steatohepatitis (non-alcoholic fatty liver disease) (*n*=72, GSE49541), renal allograft tissue from patients after allograft renal transplantation (*n*=48, GSE25902) and lung tissue from patients with or without interstitial lung disease (*n*=219, GSE47460).

Statistical analyses
--------------------

The results were expressed as the mean+s.e.m. The graphs and statistical analyses were performed using GraphPad Prism version 5.02 (GraphPad Prism, La Jolla, CA, USA). Analyses were performed using Student's *t*-test (comparison with the control group), while multiple comparisons between different groups were performed using the one-way analysis of variance with the Bonferroni *post hoc* test. *P*\<0.05 was considered significant. Correlations were assessed using Pearson's correlative analysis, and dot plots were generated. For *in vitro* experiments, no statistical method was used to predetermine the sample size. For *in vivo* experiments, the sample size was estimated using power analysis---that is, a difference of 20% with a power of 80% (1−*β*) and an *α* of 0.05. For all *in vivo* studies, mice were blindly randomized into different groups. The investigators were not blinded to allocation for the *in vivo* experiments but were blinded to allocation for immunohistochemical analyses. Quantitative data analysis was performed in a blinded manner. No samples that were fully processed for different assays, western blotting or immunohistochemical analysis were excluded. No mice that completed the studies were excluded from the analyses.

Results
=======

Upregulation of ITGA11 in the fibrotic livers in CCl~4~-induced mouse models
----------------------------------------------------------------------------

We examined the ITGA11 expression in the mouse fibrotic livers as compared with the healthy livers. Repeated administration of CCl~4~ for 4 and 8 weeks in mice resulted in extensive bridging fibrosis with a substantial deposition of collagen I and HSC activation (increased desmin expression) compared with olive-oil-treated non-fibrotic control livers ([Figure 1a](#fig1){ref-type="fig"} and [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). The gene expression of major fibrotic parameters, including *Col1a1* (Collagen I), *Des* (desmin), *Acta2* (α-SMA), *Col3a1* (Collagen-III), *TGFβ*, *Timp1* (tissue inhibitor of matrix metalloproteases), *Mmp9 and Mmp13* (matrix metalloproteases 9 and 13) and *PdgfβR* (platelet-derived growth factor receptor beta), were significantly increased in the CCl~4~-treated fibrotic livers versus olive-oil-treated control livers ([Figure 1b](#fig1){ref-type="fig"}). Importantly, both the protein and gene expression levels of *Itga11* were correlatively upregulated with an increasing degree of liver fibrosis (collagen-I and desmin), and the expression was localized in the areas of active fibrogenesis ([Figures 1a--c](#fig1){ref-type="fig"}). Because the ITGA11 subunit forms a dimer with the ITGB1 subunit (Integrin beta 1), we also assessed the expression of ITGB1 and observed higher expression of *Itgb1* (Integrin beta 1) mRNA expression in 8-weeks CCl~4~-treated fibrotic livers as compared with the control livers (*P*=0.06) ([Figure 1b](#fig1){ref-type="fig"}). Additionally, we observed very low expression of ITGA11 in normal healthy livers ([Figure 1a](#fig1){ref-type="fig"}) and other normal mouse organs---that is, the heart, kidneys, lungs and spleen---mainly confined to the collagen-I-positive regions ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

Upregulation and myofibroblast-specific localization of ITGA11 expression in the human fibrotic livers
------------------------------------------------------------------------------------------------------

In the human cirrhotic livers, ITGA11 was highly overexpressed and specifically co-localized with α-SMA-positive HSCs ([Figure 1d](#fig1){ref-type="fig"}). Analysis in non-alcoholic fatty liver disease patients showed a significant induction of ITGA11 expression (*P*\<0.04) in the advanced liver fibrosis stages F3 or F4 (severe fibrosis, *n*=32) compared with stage F0 or F1 (mild fibrosis, *n*=40) ([Figure 1e](#fig1){ref-type="fig"}) as determined from transcriptome data analysis (GEO accession number: GSE49541).

Induction of ITGA11 expression following TGFβ-mediated HSC activation
---------------------------------------------------------------------

To establish that ITGA11 is specifically induced in primary human activated HSCs (liver myofibroblasts), we examined its expression in TGFβ-activated HSCs compared with non-activated control HSCs. As shown in [Figures 2a and b](#fig2){ref-type="fig"}, upon TGFβ-mediated HSC activation, ITGA11 protein expression was significantly increased concomitantly with collagen-I and the myofibroblast-specific marker α-SMA. By contrast, ITGA11 expression remained undetectable in human hepatocytes (HepG2) and human monocytes (THP1) ([Figures 2b and c](#fig2){ref-type="fig"}). Furthermore, mRNA analysis showed marked induction of several genes associated with the myofibroblastic phenotype, including Col1a1, Acta2, Desmin, Vimentin, TIMP1 and PDGFβR, and ITGA11 and ITGB1 ([Figure 2d](#fig2){ref-type="fig"}).

ITGA11 depletion in HSCs attenuates HSC activation and differentiation
----------------------------------------------------------------------

To implicate ITGA11 in HSC activation, we generated human HSCs with stable ITGA11 knockdown (ITGA11-KD) using shRNA-ITGA11 and evaluated whether the loss of ITGA11 affects their phenotype and TGFβ-mediated activation and differentiation. The knockdown of ITGA11 was confirmed using western blotting and qPCR, with 90% reduction in ITGA11 expression compared with scrambled-shRNA-transfected control HSCs ([Figures 3a and c](#fig3){ref-type="fig"}). Significantly, we found that ITGA11-KD HSCs strongly inhibited TGFβ-induced differentiation (α-SMA) and ECM production (collagen-I and vimentin) compared with control (scrambled shRNA) HSCs ([Figures 3b and c](#fig3){ref-type="fig"}). ITGA11 knockdown significantly downregulated mRNA transcripts of major fibrotic parameters such as collagen-I, Acta2, Vimentin, TIMP1 and Paxillin (ECM adhesion protein), whereas no effect on ITGB1 and ITGA5 mRNA levels was observed ([Figure 3c](#fig3){ref-type="fig"}). Notably, scrambled-shRNA-transfected control HSCs demonstrated increased α-SMA expression ([Figure 3c](#fig3){ref-type="fig"}) compared with control HSCs (non-transfected) as shown in [Figure 2d](#fig2){ref-type="fig"}.

We further analyzed ITGA11-KD and control HSCs for the mRNA profiling of 84 fibrosis parameters using the RT^2^ profiler human fibrosis array. Interestingly, we found the downregulation of the following 19 fibrosis-related genes: (a) pro-fibrotic and inflammatory cytokines, for example, Acta2, MCP1 (or CCL2) and interleukin-1β (b) ECM-remodeling and adhesion genes, for example, Collagen 1A2, MMP1, MMP3, MMP9, TIMP1, TIMP3, PLAT, PLAU, SERPINE1 and ITGA2; and (c) TGFβ superfamily genes, for example, C/EBP, STAT1, TGFBR1, TGFBR2, TGIF1 and THBS2 ([Table 1](#tbl1){ref-type="table"}). These findings suggest that ITGA11 indeed regulates HSC activation at different levels. Notably, ITGA11 depletion inhibited the expression of TGFβ receptors (TGFβR1 and TGFβR2) and TGIF1 (TGFβ inducing factor 1), implicating a role of ITGA11 in the negative feedback regulation of the TGFβ-signaling pathway ([Table 1](#tbl1){ref-type="table"}).

ITGA11 depletion in HSCs inhibits the phenotypic transformation of HSCs
-----------------------------------------------------------------------

Because HSCs can migrate to the sites of tissue injury during fibrogenesis and differentiate into contractile myofibroblasts that promote liver stiffness, we examined the effect of ITGA11 knockdown on migration using wound-healing assays and contractility of HSCs using the 3D collagen contraction assay. ITGA11-KD HSCs displayed attenuated migration after 24 h compared with control HSCs upon migratory stimulation with 10% FBS (approximately 30% inhibition) or TGFβ (approximately 60% inhibition) ([Figure 4a](#fig4){ref-type="fig"} and [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). Furthermore, ITGA11-KD HSCs displayed significantly diminished collagen gel contraction upon TGFβ activation compared with scrambled control HSCs (approximately 60% inhibition; [Figures 4b and c](#fig4){ref-type="fig"}). Because these effects can be related to differences in proliferation, we performed the Alamar Blue assay at different incubation times (0, 24 and 48 h) with or without TGFβ. We observed approximately 10% inhibition in cell proliferation after 24 h of TGFβ incubation and approximately 20% inhibition in cell proliferation after 48 h of incubation ([Figure 4d](#fig4){ref-type="fig"}). Therefore, the differences observed in wound-healing assays and contraction assays (60% inhibition) could partially reflect the reduced proliferative activity of ITGA11-KD HSCs ([Figures 4a--d](#fig4){ref-type="fig"}).

To further investigate the significance of ITGA11 on the functional characteristics of HSCs, we studied their adhesion to the surface and changes in protrusions. We performed phalloidin/ITGA11 co-immunostaining and found that ITGA11-KD HSCs have significantly reduced actin fibers and focal adhesion points compared with control scrambled HSCs ([Figure 4e](#fig4){ref-type="fig"}). To further confirm these changes in adhesion, we performed AFM to visualize the detailed focal adhesions. As shown in [Figure 4f](#fig4){ref-type="fig"}, many focal adhesions were present in the scrambled control HSCs as compared with ITGA11-KD HSCs where the cellular edges were blunted, indicating the loss of focal adhesions and poor adhesion to the surface. We also quantified the cell height from the surface because if the cells are tightly adherent, the cells have less height compared with the weakly adhered cells. Interestingly, we observed that the height of the control scrambled HSCs was significantly lower than that of ITGA11-KD HSCs (1.10±0.29 versus 1.465±0.54 μm) ([Figure 4f](#fig4){ref-type="fig"}), reflecting an important role of ITGA11 in cellular adhesion. In addition, we performed vinculin and phalloidin staining on TGFβ-activated control scrambled HSCs and ITGA11-KD HSCs and observed highly significantly reduced vinculin and phalloidin staining as shown in [Figure 4g](#fig4){ref-type="fig"}. Notably, vinculin and phalloidin staining was significantly differently localized in ITGA11-KD cells as compared with control HSCs as depicted in higher magnification images ([Figure 4g](#fig4){ref-type="fig"}). These data strongly demonstrate that ITGA11 is a functionally and distinctively active receptor in the regulation of the activation and differentiation of HSCs and mediate the contraction, migration and adhesion of HSCs.

Crosstalk between ITGA11 and the Hedgehog signaling pathway
-----------------------------------------------------------

Recently, it has been shown that myofibroblasts mainly originate from Gli1+ (glioma-associated oncogene homolog 1) perivascular progenitor cells.^[@bib32]^ Because Gli1 is a transcription factor of the hedgehog pathway, we investigated the effect of ITGA11-KD on the expression levels of hedgehog pathway-related components---that is, sonic hedgehog ligand (SHH), patched-1 receptor (PTCH1), Smoothened (SMO), a downstream protein in the pathway, and signaling molecules Gli1, Gli2 transcription factors and sex-determining region Y box 9 (Sox9) in HSCs. Interestingly, we found that the mRNA expression levels of hedgehog pathway-related components are highly significantly inhibited following ITGA11 knockdown ([Figure 5a](#fig5){ref-type="fig"}). Furthermore, TGFβ-induced expression of Gli1 and Sox9 was significantly inhibited in ITGA11-KD HSCs as compared with control scrambled HSCs ([Figure 5b](#fig5){ref-type="fig"}), suggesting that ITGA11 mediates its effect via the hedgehog pathway, or ITGA11 may be involved in the downstream hedgehog signaling pathway and positively regulate Gli1 and Sox9 expression. To study the direct involvement of hedgehog and ITGA11, we incubated control and ITGA11-KD HSCs with 5 μg ml^−1^ of Shh ligand and investigated ITGA11 gene expression. We found control HSCs showed the induction in ITGA11 expression following incubation with Shh ligand compared with ITGA11-KD, further demonstrating that ITGA11 is downstream of the hedgehog signaling pathway and regulates HSC activation and differentiation ([Figure 5c](#fig5){ref-type="fig"}). We further examined the expression of Gli1 on α-SMA-positive myofibroblasts and confirmed the perivascular co-localization of Gli1 and α-SMA ([Figure 5d](#fig5){ref-type="fig"}), corroborating the findings of a recent study.^[@bib32]^

Hedgehog pathway inhibition attenuates fibrotic parameters in human HSCs *in vitro* and human liver slices *ex vivo*
--------------------------------------------------------------------------------------------------------------------

To further understand the mechanism involved in ITGA11-mediated regulation of myofibroblast differentiation, we examined the effect of a selective hedgehog signaling pathway inhibitor, LDE225 (or Erismodegib), on human HSC activation *in vitro* in human HSCs and *ex vivo* in human liver slices. Treatment of HSCs with LDE225 led to a significant reduction in TGFβ-induced α-SMA, collagen I and vimentin gene and protein expression ([Figure 5e](#fig5){ref-type="fig"} and [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). Because ITGA11-KD cells had an attenuated capacity of collagen production, we examined the effect of hedgehog inhibition on HSC contraction and found that LDE225 (10 μ[M]{.smallcaps}) significantly reduced TGFβ-induced collagen gel contraction ([Figure 5f](#fig5){ref-type="fig"}).

Importantly, LDE225 (10 or 15 μ[M]{.smallcaps}) treatment of *ex vivo* human liver slices resulted in a significant inhibition of fibrotic genes (Acta2, TIMP-1 and PDGFβR) ([Figure 5g](#fig5){ref-type="fig"}) and attenuation of the expression of ITGA11 and ITGA5 (angiogenesis parameters) and hedgehog signaling molecules Sox9 and Gli1 ([Figure 5h](#fig5){ref-type="fig"}). Altogether, these results confirm a potential link between ITGA11 and the hedgehog pathway.

Inhibition of the hedgehog pathway ameliorates fibrogenesis *in vivo* in an acute liver injury mouse model
----------------------------------------------------------------------------------------------------------

We further investigated the effect of a selective hedgehog signaling pathway inhibitor, LDE225 (or Erismodegib), *in vivo* in an acute liver fibrogenesis mouse model. In the CCl~4~-induced acute liver injury mouse model, hedgehog inhibitor significantly inhibited collagen-I, desmin and α-SMA protein expression ([Figure 6a](#fig6){ref-type="fig"} and [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). In addition, we observed a significant reduction in the mRNA expression of (a) fibrogenic parameters (*Col1a1*, *Acta2*, *Desmin*, *Vimentin* and *Tgfβ*), (b) angiogenesis markers (*Vegf*, *Itga5* and *Cd31*) and (c) hedgehog pathway-related genes (*Gli1* and *Sox9*) ([Figure 6b](#fig6){ref-type="fig"}) with significantly reduced ITGA11 expression ([Figure 6b](#fig6){ref-type="fig"}). We also observed a reduction (*P*=0.06) in alanine aminotransferase levels following treatment with LDE225, suggesting the attenuation of liver inflammation ([Figure 6c](#fig6){ref-type="fig"}).

Myofibroblast-specific localization of ITGA11 in mouse and human fibrotic kidneys
---------------------------------------------------------------------------------

Because renal myofibroblasts are the major mediator of ECM deposition and scar tissue formation in kidney fibrosis, we examined the role of ITGA11 in human fibrotic kidneys and UUO kidney fibrosis mouse models. After 7 days of UUO, mice developed extensive renal fibrosis as shown by the substantial deposition of collagen-I and enhanced α-SMA expression in the fibrotic kidneys compared with that in the contralateral control kidneys ([Figure 7a](#fig7){ref-type="fig"}). There was strong expression of ITGA11 in the UUO kidneys in the tubulointerstitium, glomerular and perivascular membrane, the areas where α-SMA was also highly expressed. By contrast, ITGA11 was weakly expressed in the glomerular mesangium in the contralateral kidneys ([Figure 7a](#fig7){ref-type="fig"}). Furthermore, in the fibrotic kidneys from UUO (3 and 7 days), we observed increased mRNA expression of *Col1a1*, *Acta2*, *Col3a1* and *Itga11* ([Figure 7a](#fig7){ref-type="fig"}). In human fibrotic kidneys, there was a significant increase in ITGA11 expression, which was specifically co-localized with α-SMA-positive cells, including vascular smooth muscle cells and interstitial fibroblasts ([Figure 7b](#fig7){ref-type="fig"}). We also correlated the interstitial fibrosis and tubular atrophy score with ITGA11 expression using clinical transcriptomic data analysis (GEO accession number: GSE25902) and found that ITGA11 expression was significantly (*P*\<0.03) induced at score 3 compared with that at scores 0--2 ([Figure 7c](#fig7){ref-type="fig"}).

Myofibroblast-specific localization of ITGA11 in the human fibrotic lungs
-------------------------------------------------------------------------

To further extend our findings, we analyzed the ITGA11 expression in fibrotic lungs from patients with idiopathic pulmonary fibrosis. We found a significant induction in the ITGA11 expression in the fibrotic lungs as compared with the healthy lungs, and ITGA11 expression was found to be specifically co-localized with α-SMA-positive myofibroblasts ([Figure 7d](#fig7){ref-type="fig"}). Furthermore, we found a highly significant increase in ITGA11 mRNA expression in the lungs from idiopathic pulmonary fibrosis patients (*P*\<0.001, *n*=123) as compared with normal lungs (*n*=96), as assessed by transcriptome data analysis (GEO accession number: GSE47460) ([Figure 7e](#fig7){ref-type="fig"}). In addition, we assessed ITGA11 expression in normal and fibrotic human lung slices and found an increased expression of fibrotic parameters (Collagen-I, Vimentin and TIMP1) with concomitant induction in the ITGA11 expression ([Figure 7f](#fig7){ref-type="fig"}).

Discussion
==========

The present study established the significance of integrin alpha11 (ITGA11), a collagen I binding receptor, in the regulation of myofibroblast phenotypic differentiation during fibrotic diseases. ITGA11 expression was substantially induced in myofibroblasts in the fibrotic liver, kidneys and lungs and co-localized with α-SMA in mouse models and human patient samples. Interestingly, the knockdown of ITGA11 in myofibroblasts (or activated HSCs) strongly inhibited their activation, differentiation, migration and contractility. Gene array showed that several fibrosis-related genes were significantly reduced after knockdown of ITGA11 in HSCs. Furthermore, our data revealed that the hedgehog signaling pathway contributed to the regulation of ITGA11 expression, and inhibition of the hedgehog pathway using a specific inhibitor attenuated early liver fibrogenesis in mice and inhibited fibrotic parameters in *ex vivo* human liver slices.

Excessive tissue scarring or fibrosis is a common feature of most chronic diseases.^[@bib15]^ During tissue injury, environmental cues and various growth factors lead to the activation and differentiation of myofibroblasts, which are the major ECM-producing fibrogenic cells.^[@bib12]^ Therefore, therapeutic intervention leading to inactivation of the myofibroblastic phenotype or reverting these cells to the quiescent state would be a rational approach to treat fibrotic diseases. Integrins are overexpressed in different cell types in response to an injury and interact with ECM proteins, allowing the cells to attach, migrate and proliferate.^[@bib16]^ During fibrogenesis, myofibroblasts produce ECM constituents, including collagens, and express integrin receptors that interact and signal via ECM proteins. Recently, integrin αv has been shown to regulate myofibroblast differentiation.^[@bib17],\ [@bib20]^ As shown in the current study, ITGA11 was highly upregulated in myofibroblasts during fibrogenesis (liver, kidney and pulmonary fibrosis as shown in mouse models and human fibrotic tissues). Furthermore, negligible expression of ITGA11 was found in healthy mouse and human tissues, suggesting that the inhibition of this receptor likely has a minimal impact on normal tissues. Strikingly, the patient transcriptomic data analysis showed a significant induction of ITGA11 at increasing stages of fibrosis in patients with non-alcoholic fatty liver disease, idiopathic pulmonary fibrosis and interstitial kidney fibrosis. Furthermore, our gene expression data in freshly isolated lung specimens from patients showed higher ITGA11 expression levels in fibrotic lungs than those in non-fibrotic lungs. These data strongly highlight ITGA11 as a promising marker in fibrogenesis that could be used to identify and segregate fibrosis stages in different organs.

During fibrogenesis, TGFβ is one of the key growth factor involved in disease progression by activated fibroblasts.^[@bib11],\ [@bib33]^ TGFβ can increase the expression of integrins,^[@bib34]^ and similarly, integrins can modulate the TGFβ/Smad pathways directly or indirectly via different mechanisms.^[@bib17]^ In the current study, ITGA11 expression in HSCs was highly upregulated in response to TGFβ activation ([Figures 2a--c](#fig2){ref-type="fig"}), corroborating with the previous findings showing TGFβ-mediated regulation of ITGA11 in Smad- and Sp1-dependent manner.^[@bib27]^ Furthermore, stable knockdown of ITGA11 in HSCs downregulated TGFβ superfamily genes (CEBPB, TGFBR1, TGFBR2 and TGIF1), demonstrating a strong negative feedback regulation of the TGFβ signaling pathway by ITGA11 in HSCs. In addition, fibrosis profiler array data revealed that ITGA11 knockdown in HSCs also reduced several pro-fibrotic and ECM remodeling genes (for example, collagen-I, MMP-1, -3, -9 and TIMP-1, -3), suggesting that ITGA11 controls ECM production and remodeling in HSCs. Integrins are also crucial receptors for the maintenance of the cytoskeleton, thereby controlling cell shape, contractility and migration. In the present study, we demonstrate that ITGA11 knockdown in HSCs led to a significant loss of focal adhesion, as shown with AFM, and a reduction in a major adhesion protein, paxillin, which regulates HSC adhesion to the matrix. As focal adhesions are crucial for cell contractility and migration, ITGA11 knockdown in HSCs led to reduced collagen gel contraction and migration.

Recent data have suggested that myofibroblasts in different fibrotic diseases originate from Gli1+ perivascular cells.^[@bib32]^ Here we also demonstrate Gli1 co-expression on perivascular αSMA-positive myofibroblasts in human fibrotic livers. Gli1 is a transcription factor of the hedgehog signaling pathway that has an important role in fibrosis, and its selective inhibition has been shown to ameliorate liver fibrosis.^[@bib35]^ In this study, hedgehog signaling pathway molecules (Gli1 and Sox9) were upregulated in both TGFβ-activated HSCs and *in vivo* in mouse liver fibrosis model. Interestingly, hedgehog pathway-related genes (Shh, Ptch1, Smo, Gli1, Gli2 and Sox9) were significantly downregulated in ITGA11-KD HSCs, and TGFβ-induced upregulation of hedgehog signaling molecules (Sox9 and Gli1) were attenuated in ITGA11 knockdown HSCs, indicating an inter-relationship between the ITGA11 and hedgehog signaling pathways. We further observed significantly increased expression of ITGA11 in Shh-treated control HSCs that was completely blocked in ITGA11-KD cells, suggesting a direct correlation between the hedgehog pathway and ITGA11. Furthermore, treatment with a specific hedgehog inhibitor, LDE225, reduced the expression of ITGA11 and several fibrosis-related genes in TGFβ-activated human HSCs and CCl~4~-induced early liver fibrogenesis mouse model. To demonstrate the impact of hedgehog inhibition on ITGA11 in clinical samples, we used precision-cut liver slices from patient-derived fibrotic livers.^[@bib36]^ Interestingly, LDE225 strongly reduced the ITGA11 expression and several fibrotic genes in these slices. These data explicitly show that the ITGA11 and hedgehog pathways regulate each other, and the inhibition of the hedgehog pathway is an interesting strategy to inhibit the ITGA11 expression. Because ITGA11 positively regulates the TGFβ and hedgehog signaling pathways, ITGA11 might be involved downstream in these signaling pathways. However, detailed promoter studies are required to elucidate the role of the TGFβ/smad3 pathway and hedgehog/Gli1 pathway and involvement of ITGA11 in these regulatory pathways.

In conclusion, ITGA11 is a highly promising target that is selectively overexpressed in myofibroblasts during fibrotic diseases and regulates myofibroblast differentiation and key phenotypic characteristics. Furthermore, our data uncovered the hedgehog signaling pathway as a mediator of the ITGA11 pathway in myofibroblasts *in vivo* and in patient fibrotic tissues *ex vivo*. Collectively, these data highlight the potential therapeutic significance of ITGA11 in liver fibrosis and suggest that the development of strategies to antagonize ITGA11 could lead to the development of novel and effective therapies against fibrotic diseases.
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![Upregulation of ITGA11 in CCl~4~-induced chronic liver fibrosis in mice and fibrotic human livers. (**a**) Collagen-I, Desmin and ITGA11-stained liver sections from olive-oil-treated (control) and CCl~4~-treated (8 weeks, fibrotic) mice. *n*=5 per group. (**b**) Gene expression of fibrotic parameters (*Col1a1*, *Col3a1*, *Tgfβ*, *Timp1*, *Mmp9* and *Mmp13*), myofibroblast activation markers (*Acta2*, *Desmin* and *Pdgfβr*) and *Itga11* and *Itgb1* in the livers of olive-oil-treated non-fibrotic control mice and CCl~4~-treated fibrotic mice (4 and 8 weeks). *n*=5 per group. ^\#^*P*\<0.05 and ^\#\#^*P*\<0.01 versus control. (**c**) Correlative analysis of ITGA11 protein and gene expression with respect to the expression of fibrotic parameters (collagen-I and Desmin). The correlations were assessed using Pearson's correlative analysis. '*R*^2^' denotes Pearson's correlation coefficient, and '*P*' denotes statistical significance. (**d**) α-SMA- and ITGA11-stained human liver sections (*n*=4). Left, healthy human liver; middle, cirrhotic human liver; right, magnified image. Upper, ITGA11 (red); middle, α-SMA (green); bottom, merged image. Nuclei are stained blue with DAPI. (**e**) I*TGA11* mRNA expression levels from publicly available transcriptome profiling data sets ([www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo)). Liver tissues affected with non-alcoholic fatty liver disease (NAFLD) stratified according to fibrosis stage: stage F0 or F1, mild fibrosis (*n*=40); stage F3 or F4, severe fibrosis (*n*=32) (GEO accession number: GSE49541).](emm2017213f1){#fig1}

![Increased ITGA11 expression in human hepatic stellate cells following TGFβ treatment. (**a**) Collagen I-, α-SMA- and ITGA11 (ITGA11, red; DAPI, blue)-stained human HSCs treated with medium (control) or TGFβ (5 ng ml^−1^). (**b**) Western blotting and (**c**) analysis of ITGA11 and β-actin expression in control and TGFβ1-activated human HSCs, human hepatocytes (HepG2) and human monocytes (THP1). 'nd' denotes not detected. (**d**) Gene expression of fibrotic parameters (*Col1α1*, *Acta2*, *desmin*, *vimentin*, *TIMP1* and *PDGFβR*) and *ITGA11* and *ITGB1* in control and TGFβ-activated human HSCs, *n*=4. \**P*\<0.05 and \*\**P*\<0.01 versus control HSCs.](emm2017213f2){#fig2}

![ITGA11 depletion in human HSCs inhibits HSC activation. (**a**) Western blotting depicting ITGA11, Collagen-I and β-actin expression in control, TGFβ-treated HSCs and TGFβ-treated ITGA11-KD (ITGA11-knockdown) HSCs. (**b**) Collagen-I-, α-SMA- and vimentin-stained control and ITGA11-KD HSCs with or without TGFβ (5 ng ml^−1^). (**c**) Gene expression of ITGA11, fibrotic parameters (*Collagen I*, *Acta2*, *vimentin* and *TIMP1*), ECM-adhesion protein (*Paxillin*), *ITGB1 and ITGA5* in control HSCs, TGFβ-treated scrambled HSCs and ITGA11-KD HSCs, *n*=4. ^\#^*P*\<0.05 and ^\#\#^*P*\<0.01 versus control HSCs. \**P*\<0.05 and \*\**P*\<0.01 versus TGFβ-treated HSCs. Control cells were transfected with control/scrambled shRNA plasmid. ITGA11-KD cells were transfected with the ITGA11 shRNA plasmid.](emm2017213f3){#fig3}

![ITGA11 depletion in HSCs inhibits phenotypic transformation of HSCs. (**a**) Percentage of wound closure (24 h) by control HSCs and ITGA11-KD HSCs under different conditions, *n*=4. ^\#^*P*\<0.05, ^\#\#^*P*\<0.01 versus control or ITGA11-KD HSCs; \**P*\<0.05. Representative images (**b**) and quantitative analysis (**c**) of 3D collagen-I gel contraction containing control versus ITGA11-KD HSCs treated with or without TGFβ (5 ng ml^−1^), *n*=4. ^\#\#^*P*\<0.01 versus control HSCs; \*\**P*\<0.01 versus TGFβ-treated HSCs. (**d**) Percentage of cell viability of control HSCs and ITGA11-KD HSCs with or without TGFβ (5 ng ml^−1^) at different time points (0, 24 and 48 h) as assessed using the Alamar Blue assay. *n*=4. ^\#^*P*\<0.05 versus control; \**P*\<0.05 and \*\**P*\<0.01 versus control or TGFβ-treated HSCs. (**e**) ITGA11-KD and control HSCs stained with phalloidin (red, first column), ITGA11 (green, second column); third column, merged image; fourth column, magnified merged image (depicting co-localization), and arrows depict the ITGA11/phalloidin co-stained protrusions. Nuclei are stained blue with DAPI. (**f**) AFM images depicting the adhesion of stained control HSCs and ITGA11-KD HSCs. The upper panel depicts microscopic images, the middle panel depicts AFM images and the bottom panel depicts the magnified edges. The right panel shows the height of cells (average±s.d., *n*=4) as measured by AFM. (**g**) Control (first column) and ITGA11-KD (second column) HSCs stained with vinculin (green, upper panel) and phalloidin (red, middle panel); lower panel, merged image. The third column shows the magnified vinculin-stained images. Nuclei are stained blue with DAPI. Control cells were transfected with control/scrambled shRNA plasmid. ITGA11-KD cells were transfected with the ITGA11 shRNA plasmid.](emm2017213f4){#fig4}

![Myofibroblastic localization of Gli1 and the effect of hedgehog inhibition on TGFβ-activated human HSCs *in vitro* and human liver slices *ex vivo*. (**a**) Gene expression of hedgehog pathway-related genes (*Shh*, *Ptch1*, *Smo*, *Gli1*, *Gli2* and *Sox9*) in ITGA11-KD HSCs versus control HSCs, *n*=3. \*\**P*\<0.01 represents significance versus control HSCs. (**b**) Gene expression of hedgehog pathway-related genes (*Sox9* and *Gli1*) in TGFβ-treated ITGA11-KD HSCs versus TGFβ-treated control HSCs, *n*=4. ^\#^*P*\<0.05 and ^\#\#^*P*\<0.01 versus control HSCs (dashed line); \**P*\<0.05 and \*\**P*\<0.01 versus TGFβ-treated HSCs. (c) Gene expression of ITGA11 in control HSCs and ITGA11-KD HSCs with or without Shh (5 μg ml^−1^), *n*=3. ^\#^*P*\<0.01 versus Shh-treated HSCs, \*\**P*\<0.01 versus control HSCs. (**d**) α-SMA and Gli1 co-immuno-stained human liver sections. Gli1 (red, first column), α-SMA (green, second column) and merged image (third column). Fourth column shows the magnified image depicting co-localization. Nuclei are stained blue with DAPI. (**e**) Collagen-I- and vimentin-stained HSCs treated with or without TGFβ (5 ng ml^−1^)±10 μ[M]{.smallcaps} of the hedgehog inhibitor (LDE225). Gene expression of fibrotic parameters collagen-I, α-SMA and vimentin in HSCs treated with medium alone, TGFβ (5 ng ml^−1^)±10 μ[M]{.smallcaps} LDE225, *n*=3. ^\#^*P*\<0.05, ^\#\#^*P*\<0.01 versus the control cells; \**P*\<0.05 versus TGFβ-treated cells. (**f**) Graph depicts % 3D collagen-I gel contraction after 24, 48 and 72 h of treatment with or without TGFβ (5 ng ml^−1^)±10 μ[M]{.smallcaps} LDE225, *n*=3. ^\#^*P*\<0.05, ^\#\#^*P*\<0.01 versus control cells; \**P*\<0.05 versus TGFβ-treated cells. Gene expression of Acta2, TIMP1, PDGFβR and Collagen-I (**g**) and ITGA11, Sox9, Gli1 and ITGA5 (**h**) in the slices obtained from fibrotic livers from human patients incubated with medium (control) or 10 or 15 μ[M]{.smallcaps} LDE225. *n*=3 patients (3 slices each). \**P*\<0.05 and \*\**P*\<0.01 versus control group. Control cells were transfected with control/scrambled shRNA plasmid. ITGA11-KD cells were transfected with the ITGA11 shRNA plasmid.](emm2017213f5){#fig5}

![Effect of hedgehog inhibition in an acute CCl~4~-induced liver injury mouse model. (**a**) Representative photomicrographs and quantitative analysis of collagen-I- and desmin-stained liver sections from normal (olive-oil-treated), vehicle-treated CCl~4~ and LDE225-treated CCl~4~ mice. (**b**) Gene expression in the livers of different treated groups, *n*=5 per group. ^\#^*P*\<0.05 and ^\#\#^*P*\<0.01 versus the olive-oil-treated normal group; \**P*\<0.05 versus CCl~4~-treated vehicle group. (**c**) The serum ALT levels of different treated groups. *n*=5 per group. ^\#\#^*P*\<0.01 versus olive-oil treated control group; *P*=0.06 versus CCl~4~-treated vehicle group.](emm2017213f6){#fig6}

![Integrin alpha 11 (*ITGA11*) overexpression in the UUO model of kidney fibrosis in mice and in fibrotic human kidneys and fibrotic lung tissues. (**a**) Collagen-I-, α-SMA- and ITGA11-stained kidney sections obtained from sham- and 7 days UUO-operated mice (*n*=4 per group). Gene expression of fibrotic parameters (*Col1A1*, *Acta2* and *Col3A1*) and *ITGA11* in the kidneys from contralateral, 3-day and 7-day UUO-operated mice, *n*=4 per group. \**P*\<0.05 and \*\**P*\<0.01 versus contralateral kidneys. (**b**) α-SMA and ITGA11 co-immunostained human fibrotic kidney sections (*n*=4 per group). Upper, ITGA11 (red); middle, α-SMA (green); bottom, merged image. Nuclei are stained blue using DAPI. The lower panel depicts the magnified image. (**c**) The *ITGA11* mRNA expression levels extracted from publicly available transcriptome profiling data sets ([www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo)). Kidney tissues stratified according to the IFTA score: 0, no fibrosis (*n*=16); 1, mild fibrosis (*n*=11); 2, moderate fibrosis (*n*=13); 3, severe fibrosis (*n*=8) (GSE25902), \**P*=0.03. (**d**) α-SMA and ITGA11 co-immunostained human lung sections (*n*=5 per group). Upper, ITGA11 (red); middle, α-SMA (green); bottom, merged image. Nuclei are stained blue using DAPI. (**e**) The *ITGA11* mRNA expression levels were extracted from publicly available transcriptome profiling data sets ([www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo)). Lung tissues with idiopathic pulmonary fibrosis (*n*=123) compared with normal controls (*n*=96) (GSE47460). \**P*\<0.001 versus normal lungs. (**f**) Heat map representation of the gene expression of ITGA11, Col1A1, Vimentin and TIMP1 in human lung slices. N1--N5 and F1--F5 denote normal and fibrotic samples, respectively.](emm2017213f7){#fig7}

###### Genes differentially expressed in ITGA11-KD cells compared with control cells characterized in the Human Fibrosis PCR Array (RT^2^ Profiler PCR Array PAHS-0120Z, SABiosciences) and analyzed using the provided RT Profiler PCR Array Data Analysis v. 3.5 software

  *Gene symbol*                                                        *Refseq*    *Description*                                                                                    *Fold regulation*
  -------------------------------------------------------------------- ----------- ----------------------------------------------------------------------------------------------- -------------------
  *Profibrotic and inflammatory cytokines*                                                                                                                                         
   **ACTA2**                                                           NM_001613   Actin, alpha 2, smooth muscle, aorta                                                                  −1.8557
   **CCL2 (MCP1)**                                                     NM_002982   Chemokine (C-C motif) ligand 2                                                                        −4.2634
   **IL-1B**                                                           NM_000576   Interleukin 1, beta                                                                                   −4.0615
                                                                                                                                                                                             
  *Extracellular matrix, ECM remodeling and cell adhesion*                                                                                                                         
   **COL1A2**                                                          NM_000089   Collagen, type I, alpha 2                                                                             −2.4318
   **MMP1**                                                            NM_002421   Matrix metallopeptidase 1 (interstitial collagenase)                                                 −60.6317
   **MMP3**                                                            NM_002422   Matrix metallopeptidase 3 (stromelysin 1, progelatinase)                                              −5.0002
   **MMP9**                                                            NM_004994   Matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase)               −1.948
   **TIMP1**                                                           NM_003254   TIMP metallopeptidase inhibitor 1                                                                     −2.0167
   **TIMP3**                                                           NM_000362   TIMP metallopeptidase inhibitor 3                                                                     −2.6427
   **PLAT**                                                            NM_000930   Plasminogen activator, tissue                                                                         −1.9079
   **PLAU**                                                            NM_002658   Plasminogen activator, urokinase                                                                      −3.6351
   **SERPINE1**                                                        NM_000602   Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1         −2.2377
   **ITGA2**                                                           NM_002203   Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)                                          −4.8299
                                                                                                                                                                                             
  *Signal transduction (TGFβ superfamily and transcription factors)*                                                                                                               
   **CEBPB**                                                           NM_005194   CCAAT/enhancer binding protein (C/EBP), beta                                                          −1.9616
   **STAT1**                                                           NM_007315   Signal transducer and activator of transcription 1                                                    −1.8557
   **TGFBR1**                                                          NM_004612   Transforming growth factor, beta receptor 1                                                           −1.9752
   **TGFBR2**                                                          NM_003242   Transforming growth factor, beta receptor 2                                                           −1.948
   **TGIF1**                                                           NM_003244   TGFB-induced factor homeobox 1                                                                        −2.0591
   **THBS1**                                                           NM_003246   Thrombospondin 1                                                                                      3.1123
   **THBS2**                                                           NM_003247   Thrombospondin 2                                                                                      −1.8947

Bold characters indicate genes upregulated or downregulated by ⩾1.8-fold.
